Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-02-22
1993-01-19
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, 514306, 514314, 514318, 514323, 514326, 514415, 514419, A61K 31445, A61K 31505, A61K 3144, A61K 3121
Patent
active
051807297
ABSTRACT:
The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.
REFERENCES:
Sharkey, J. et al, Eur J Pharmacol 149(1-2): 171-174 Mar. 1988.
Schlemmer et al., Soc. Neurosci. Abstr. 12(1):480 (1986).
Taylor et al., Drug Development Research 11:65-70 (1987).
Snyder et al., J. Neuropsychiatry 1:7-15 (1989).
Kosten, J. Nervous and Mental Disease 177:379-389 (1989).
Hock et al., Drug Development Research 6:301-311 (1985).
Ferris et al., Life Sciences 38:2329-2337 (1986).
Ogren et al., Eur. J. Pharmacology 102:459-474 (1984).
Kuhar et al. (1988) NIDA Monograph 88: 14-21.
Du Pont Merck Pharmaceutical Company
Ferguson Blair Q.
Gardner Diane
Waddell Frederick E.
LandOfFree
Use of sigma receptor antagonists for treatment of cocaine abuse does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of sigma receptor antagonists for treatment of cocaine abuse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of sigma receptor antagonists for treatment of cocaine abuse will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-102279